Mantle Cell Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Suspended
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
B
Treatment of Chinese Patients With B-Cell Malignancies With BGB-16673, a Burton Tyrosine Kinase-Targeted Protein-Degrader
Recruiting
  • B-cell Malignancy, Low-grade
  • +4 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai JiaoTong University School of Medicine
2022-04-05
Apr 5, 2022
M
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-04-05
Apr 5, 2022
A
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • ClonoSEQ
  • Palo Alto, California
    Stanford Cancer Center
2022-04-04
Apr 4, 2022
H
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Recruiting
  • Mantle Cell Lymphoma
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
2022-03-31
Mar 31, 2022
W
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma
Active, not recruiting
Has Results
  • Mantle Cell Lymphoma
  • Tampa, Florida
  • +3 more
2022-03-26
Mar 26, 2022
Q
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
2022-03-11
Mar 11, 2022
I
A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +12 more
2022-03-24
Mar 24, 2022
N
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma - 2021
Completed
  • Mantle Cell Lymphoma
  • Lymphoma, Mantle Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-24
Mar 24, 2022
J
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Enrolling by invitation
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +165 more
2022-03-24
Mar 24, 2022
J
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting
  • Mantle Cell Lymphoma
  • Tucson, Arizona
  • +202 more
2022-03-24
Mar 24, 2022
C
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Active, not recruiting
  • Adult Immunoblastic Lymphoma
  • +12 more
  • Cytology Specimen Collection Procedure
  • Birmingham, Alabama
  • +129 more
2022-03-23
Mar 23, 2022
A
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • New Orleans, Louisiana
  • +3 more
2022-03-22
Mar 22, 2022
T
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +4 more
  • Ublituximab
  • +2 more
  • Birmingham, Alabama
  • +167 more
2022-03-22
Mar 22, 2022
U
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • Vancouver, British Columbia, Canada
  • +3 more
2022-03-17
Mar 17, 2022
T
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • Ibrutinib 560 mg
  • +3 more
  • Bruges, Belgium
  • +39 more
2022-03-03
Mar 3, 2022
F
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
F
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Recruiting
  • Acute Biphenotypic Leukemia
  • +18 more
  • Aurora, Colorado
  • +2 more
2022-03-02
Mar 2, 2022
J
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Not yet recruiting
  • B-Cell Lymphoma
  • +8 more
  • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
  • Pittsburgh, Pennsylvania
    AHN Cancer Institute - West Penn Hospital
2022-03-08
Mar 8, 2022
A
A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies
Active, not recruiting
  • Lymphoma, B-Cell
  • +8 more
  • Scottsdale, Arizona
  • +9 more
2022-03-10
Mar 10, 2022
S
Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma - 2021
Terminated
  • Mantle Cell Lymphoma
  • Mainz, Germany
  • +18 more
2022-02-24
Feb 24, 2022
M
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
Active, not recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
B
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
2022-03-08
Mar 8, 2022
C
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors
Recruiting
  • Malignancy
  • +14 more
  • Scottsdale, Arizona
  • +17 more
2022-03-07
Mar 7, 2022
U
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022